EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer
JCO Precision Oncology · 2026-05 · 10 (5)
DOI: 10.1200/po-25-01229 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-05. Verfasst von Toshiaki Takahashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, …. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The EXOsome and cell-free microRNAs (miRNAs) of anti–epidermal growth factor receptor (EGFR) Resistance (EXONERATE) study previously developed and validated a liquid biopsy to predict the efficacy of first-line anti-EGFR therapy in metastatic colorectal cancer (mCRC) from treatment-naïve blood samples. This study evaluates the performance of the EXONERATE assay during therapy as a tool for monitoring the emergence of anti-EGFR resistance before it becomes clinically or radiologically apparent. METHODS Retrospective, single-center, longitudinal, REMARK-compliant biomarker study assessing the ability of a liquid biopsy to predict response to anti-EGFR monoclonal antibodies and to track resistance development longitudinally. Fifty-two patients with RAS wild-type mCRC provided 142 plasma samples during administration of first-line anti-EGFR–based therapy. RESULTS Baseline EXONERATE scores predicted response with 83.3% specificity and 77.3% sensitivity (area under the receiver operating characteristic curve [AUROC] = 89.4%). Longitudinal analyses demonstrated that biomarker changes closely tracked tumor burden and anticipated clinical and radiological progression, outperforming conventional tumor markers CEA and CA19-9. Stepwise optimization produced a reduced panel (four cell-free-miRNAs and five exo-miRNAs), EXONERATE-Tracking Response and Clinical Evolution (TRaCE), which retained high predictive accuracy (AUROC = 94.4%) while enabling more practical, repeated monitoring. EXONERATE-TRaCE values increased during the 3 months preceding the first clinical or radiological evidence of progression and reliably detected early progression in both left- and right-sided tumors, including patients with lung metastases, and identified resistance up to 3 months before radiological confirmation. CONCLUSION EXONERATE-TRaCE extends the predictive utility of the original EXONERATE assay into a practical monitoring tool. This liquid biopsy detects emerging anti-EGFR resistance earlier than conventional markers and may inform treatment monitoring and support timely clinical decision making in mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Monrovia, CA.
- Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
- Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- City of Hope Medical Center, Duarte, CA.
- Department of Medical Oncology, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain.
ORCID-Profile: Toshiaki Takahashi, Alessandro Mannucci, Kunitoshi Shigeyasu, Scott Kopetz, Marwan Fakih, Joan Maurel, Toshiyoshi Fujiwara, Ajay Goel
Förderung
- NCI NIH HHS
Zitieren
APA
Takahashi, T., Mannucci, A., Shigeyasu, K., Kopetz, S., Fakih, M., Maurel, J., Fujiwara, T., & Goel, A. (2026). EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 10(5). https://doi.org/10.1200/po-25-01229
Vancouver
Takahashi T, Mannucci A, Shigeyasu K, Kopetz S, Fakih M, Maurel J, et al. EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology. 2026;10(5). doi:10.1200/po-25-01229
BibTeX
@article{Takahashi2026,
author = {Takahashi, Toshiaki and Mannucci, Alessandro and Shigeyasu, Kunitoshi and Kopetz, Scott and Fakih, Marwan and Maurel, Joan and Fujiwara, Toshiyoshi and Goel, Ajay},
title = {EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {5},
doi = {10.1200/po-25-01229}
}
EUVIMED